<DOC>
	<DOCNO>NCT02149329</DOCNO>
	<brief_summary>A multicenter open-label non-inferiority randomize clinical trial compare safety ( non-inferiority ) short antibiotic treatment ( 72 hour ) anti-pseudomonal carbapenem regard treatment failure comparison extend treatment ( least 9 day ) high-risk febrile neutropenia hematology patient receive standard antimicrobial prophylaxis .</brief_summary>
	<brief_title>Short Versus Extended Antibiotic Treatment With Carbapenem High-risk Febrile Neutropenia Hematology Patients With FUO</brief_title>
	<detailed_description>Episodes fever common patient undergoing intensive chemotherapy treatment malignant hematological disease . More 80 % patient experience one episodes fever first cycle chemotherapy . Only 20-30 % patient clinically documented focus mostly include infection skin , intestinal tract lung , 10-25 % patient microbiologically proven bacteremia episode . Patients malignant hematological disease intensive chemotherapy induce neutropenia extremely prone overwhelm bacterial infection . Therefore , empirical antibiotic treatment initiate first occurrence fever , even apparent cause fever evident . Most protocols advice treatment broad-spectrum antibiotic , mostly anti-pseudomonal carbapenems fourth generation anti-pseudomonal cephalosporin . Prolonged continuation treatment may induce bacterial resistance . In view possible emergence bacterial resistance due prolong antibiotic administration , continuation recovery neutropenia suboptimal costly long hospital admission , high antibiotic cost possible adverse reaction . Recent observational data ( Slobbe et al ) show adult hematological patient febrile neutropenia , discontinuation empiric antibacterial therapy three day safe infectious etiology find , even case persistent fever . However RCT hitherto perform support observational data . This study compare safety ( non-inferiority ) short treatment ( 72 hour ) versus extend treatment ( least 9 day ) anti-pseudomonal carbapenem hematology patient unexplained high risk febrile neutropenia . We hypothesize restrictive use broad-spectrum antibiotic use three day unexplained fever neutropenic hematology patient non-inferior present extend use least 9 day would lead restrictive use antibiotic less multiresistant strain bacteria , cost hospitalization length future .</detailed_description>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Febrile Neutropenia</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Meropenem</mesh_term>
	<mesh_term>Thienamycins</mesh_term>
	<mesh_term>Imipenem</mesh_term>
	<mesh_term>Antibiotics , Antitubercular</mesh_term>
	<mesh_term>Cilastatin</mesh_term>
	<criteria>1 . Patients malignant hematological disease treat cytotoxic chemotherapy stem cell transplantation ; 2 . Highrisk neutropenia ( Absolute neutrophil count ( ANC ) &lt; 0.5x109/L expect last long 7 day ) ; 3 . Fever ( One single measure tympanic membrane temperature &gt; 38.5°C temperature &gt; 38.0°C 2 subsequent measurement separate least 2 hour ) ; 4 . Age 18 year old ; 5 . Written informed consent . 1 . Contraindications use imipenemcilastatin meropenem allergy , previous severe sideeffects previous microbiological culture carbapenemresistant microorganism ( ) . 2 . Corticosteroid use ≥10 mg per day prednisolone equivalent previous 7 day . 3 . Clinically microbiologically document infection . 4 . Symptoms septic shock ( systolic blood pressure &lt; 90 mm Hg unresponsive fluid resuscitation and/or oliguria ( urine production &lt; 500mL/day ) . 5 . Previous enrollment study episode neutropenia . 6 . Any critical illness Intensive Care Unit treatment require . 7 . Legal incompetency</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>fever</keyword>
	<keyword>neutropenia</keyword>
	<keyword>febrile neutropenia</keyword>
	<keyword>carbapenem</keyword>
	<keyword>imipenem</keyword>
	<keyword>meropenem</keyword>
	<keyword>antibiotic stewardship</keyword>
	<keyword>hematology</keyword>
	<keyword>oncology</keyword>
</DOC>